<DOC>
	<DOCNO>NCT02570373</DOCNO>
	<brief_summary>The purpose study characterize elimination guselkumab glycoform variant follow single intravenous ( IV ) administration guselkumab 10 milligram per kilogram ( mg/kg ) dose healthy participant .</brief_summary>
	<brief_title>A Study Characterize Elimination Guselkumab Glycoform Variants Healthy Participants</brief_title>
	<detailed_description>This open-label single-dose study healthy participant . All participant receive single intravenous ( IV ) infusion guselkumab dose 10 milligram per kilogram ( mg/kg ) 60 minute Day 1 . After administration study drug Day 1 , participant stay clinical study unit discharge assessment Day 2 . Participants require return study center outpatient visit include safety assessment Day 85 study drug administration . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Participants must healthy man woman clinically significant abnormality basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening Participants must otherwise healthy basis clinical laboratory test perform Screening . If result serum chemistry panel , hematology , urinalysis outside normal reference range , subject may include investigator judge abnormalities deviation normal clinically significant appropriate reasonable population study . This determination must record participant 's source document initial investigator Have weight range 60.0 kilogram ( kg ) 100.0 kg , inclusive , male ; weight range 50.0 kg 90.0 kg , inclusive , female . Have body mass index 18.5 kilogram per meter^2 ( kg/m^2 ) 30.0 kg/m^2 , inclusive A woman must negative serum ( beta human chorionic gonadotropin [ beta hCG ] ) test Screening Day 1 Before drug administration , woman must either childbearing potential ( Not childbearing potential : Premenarchal ; postmenopausal ( great 45 year age amenorrhea least 12 month , age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 international Units/ Liter ) ; permanently sterilize ( eg , tubal occlusion , hysterectomy , bilateral salpingectomy ) ; otherwise incapable pregnancy ) OR childbearing potential practicing highly effective method birth control consistent local regulation regard use birth control method subject participate clinical study ( establish use oral , injected implant hormonal method contraception ; placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; barrier method : condom spermicidal foam/gel/film/cream/suppository occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ; male partner sterilization ( vasectomized partner sole partner participant ) ; true abstinence [ line prefer usual lifestyle participant ] ) Participant currently history clinically significant medical illness medical disorder investigator considers exclude subject , include ( limited ) , neuromuscular , hematological disease , immune deficiency state , respiratory disease , hepatic gastrointestinal ( GI ) disease , neurological psychiatric disease , ophthalmological disorder , neoplastic disease , renal urinary tract disease , dermatological disease Participant currently undergo previously undergone allergy immunotherapy history anaphylactic reaction Participant major surgery ( eg , require general anesthesia ) within 8 week screen , fully recover surgery , surgery plan time participant expect participate study ( 16 week ) Participant previously receive guselkumab Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 3 month 5 halflives ( whichever longer ) study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Guselkumab</keyword>
</DOC>